Sennoside A (SA) is a natural dianthrone glycoside mainly from medicinal plants of Senna and Rhubarb. SA possesses numerous pharmacological properties, such as laxative, anti-obesity, hypoglycemic, hepatoprotective, anti-fibrotic, anti-inflammatory, anti-tumor, anti-bacterial, anti-fungal, anti-viral, and anti-neurodegenerative activities[3]. Sennoside A is a new scaffold for the development of HIV-1 dual RT (Reverse Transcriptase) inhibitors. Sennoside A also affected HIV-1 IN activity in vitro and HIV-1 replication in cell-based assays[4]. Plasma GLP-1 (Glucagon-like peptide-1) and insulin were markedly elevated by SA (Sennoside A) at the dosage of 45 mg/kg/day. Meanwhile, the increased phosphorylation status of EKR1/2 and prohormone convertase 1/3 (PC1/3) proteins were observed in the colon of SA-treated mice[5]. Sennoside A administration markedly improved the indices in T2D mice and obesity-related traits including blood glucose level, body weight, lipid metabolism disorder, and insulin resistance. Sennoside A also reduced inflammation and increased tight junction proteins in the ileum in gene-deficient mice via gut microbiota alteration[6].
Sennoside A/番泻苷A 细胞实验
Cell Line
Concentration
Treated Time
Description
References
NCI-H716 cells
100 μM
24 h
To investigate the effect of Sennoside A on palmitic acid-induced stress responses in L-cells. Results showed that Sennoside A blocked PA-induced apoptosis and mitochondrial membrane potential reduction, and reduced ATP elevation.
Acta Pharm Sin B. 2019 Jul;9(4):758-768.
Pseudomonas aeruginosa PAO1
50 and 100 mg/ml
24 h
To evaluate the effect of Sennoside A on the growth of PAO1, results showed that 50 and 100 mg/ml of Sennoside A did not inhibit the growth of PAO1.
Front Microbiol. 2022 Nov 3;13:1042214.
SMMC-7721 cells
25 μM, 50 μM, 100 μM
24 h and 48 h
SA had no significant effect on the proliferation of SMMC-7721 cells
Front Pharmacol. 2021 Jan 12;11:566099.
HepG2 cells
25 μM, 50 μM, 100 μM
24 h and 48 h
SA inhibited the proliferation of HepG2 cells in a concentration-dependent manner
Front Pharmacol. 2021 Jan 12;11:566099.
C8166 cells
2.27 μM
72 h
To evaluate the inhibitory effect of Sennoside A on HIV-1-induced cytopathic effects, the results showed an IC50 value of 2.27 μM.
Front Microbiol. 2023 Sep 25;14:1270258.
Sennoside A/番泻苷A 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
C57BL/6J mice
High-fat diet-induced obese model
Drinking water
30 mg/kg
Once daily for 8 weeks
To investigate the effect of Sennoside A on insulin sensitivity in high-fat diet-induced obese mice. Results showed that Sennoside A improved insulin sensitivity, restored plasma GLP1 levels and Glp1 mRNA expression in the colon, and restored gut microbiota and colonic mucosal structure.
Acta Pharm Sin B. 2019 Jul;9(4):758-768.
Chinese cabbage, Drosophila melanogaster, Caenorhabditis elegans
Chinese cabbage infection model, Drosophila melanogaster infection model, Caenorhabditis elegans infection model
Added to the culture medium
50 and 100 mg/ml
Single administration, lasting 12 hours
To evaluate the effect of Sennoside A on the pathogenicity of PAO1, results showed that Sennoside A significantly reduced the infection area of PAO1 in Chinese cabbage and increased the survival rate of Drosophila melanogaster and Caenorhabditis elegans.
Front Microbiol. 2022 Nov 3;13:1042214.
BALB/c nude mice
Orthotopic xenograft tumor model
Intraperitoneal injection
10 mg/kg
Once daily for 14 days
SA significantly inhibited the growth and intrahepatic metastasis of HepG2-Luciferase cells
Front Pharmacol. 2021 Jan 12;11:566099.
Rats
Constipation model
Oral
0.1 mg/kg
Once daily for 7 days
To evaluate the effect of Sennoside A on constipation model rats, the results showed that Sennoside A significantly improved constipation symptoms.
搜索
